[go: up one dir, main page]

ATE341309T1 - Pulmonale arzneistoffverabreichung - Google Patents

Pulmonale arzneistoffverabreichung

Info

Publication number
ATE341309T1
ATE341309T1 AT99962010T AT99962010T ATE341309T1 AT E341309 T1 ATE341309 T1 AT E341309T1 AT 99962010 T AT99962010 T AT 99962010T AT 99962010 T AT99962010 T AT 99962010T AT E341309 T1 ATE341309 T1 AT E341309T1
Authority
AT
Austria
Prior art keywords
formulation
drug administration
pulmonary drug
pulmonary
dispenser
Prior art date
Application number
AT99962010T
Other languages
English (en)
Inventor
Pankaj Modi
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Application granted granted Critical
Publication of ATE341309T1 publication Critical patent/ATE341309T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99962010T 1998-12-21 1999-12-16 Pulmonale arzneistoffverabreichung ATE341309T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11324398P 1998-12-21 1998-12-21
US09/397,102 US6294153B1 (en) 1998-12-21 1999-09-16 Aerosol pharmaceutical formulation for pulmonary and nasal delivery

Publications (1)

Publication Number Publication Date
ATE341309T1 true ATE341309T1 (de) 2006-10-15

Family

ID=26810843

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99962010T ATE341309T1 (de) 1998-12-21 1999-12-16 Pulmonale arzneistoffverabreichung

Country Status (13)

Country Link
US (1) US6294153B1 (de)
EP (1) EP1143931B1 (de)
JP (1) JP3818852B2 (de)
AT (1) ATE341309T1 (de)
AU (1) AU759051B2 (de)
CA (1) CA2353847C (de)
DE (1) DE69933472T2 (de)
DK (1) DK1143931T3 (de)
ES (1) ES2274651T3 (de)
MX (1) MXPA01006377A (de)
NZ (1) NZ512272A (de)
PT (1) PT1143931E (de)
WO (1) WO2000037052A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6350432B1 (en) * 1999-03-19 2002-02-26 Generex Pharmaceuticals Incorporated Pressurized container having an aerosolized pharmaceutical composition
ES2529300T3 (es) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
EP1575976A4 (de) 2001-11-02 2006-08-23 Insert Therapeutics Inc Verfahren und zusammensetzungen zur therapeutischen verwendung von rna-interferenz
MXPA04004730A (es) * 2001-11-19 2004-07-30 Becton Dickinson Co Composiciones farmaceuticas en forma particulada.
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
KR20050049525A (ko) * 2002-10-11 2005-05-25 가부시키가이샤산와카가쿠켄큐쇼 Ｇｌｐ-1 유도체 및 그의 경점막 흡수형 제제
US7456153B2 (en) * 2002-11-14 2008-11-25 Adherex Technologies Inc. Compounds and methods for modulating functions of classical cadherins
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
CA2550811C (en) * 2003-12-24 2012-05-01 Jane Hirsh Temperature-stable formulations, and methods of development thereof
US7491263B2 (en) 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
ES2704482T3 (es) 2004-11-24 2019-03-18 Meda Pharmaceuticals Inc Composiciones que comprenden azelastina y sus métodos de uso
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
TWI335352B (en) 2005-03-31 2011-01-01 Calando Pharmaceuticals Inc Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
EP2202239A1 (de) 2005-11-01 2010-06-30 Alnylam Pharmaceuticals Inc. RNAi-Hemmung von Influenza-Virus-Neubildungen
US8229398B2 (en) * 2006-01-30 2012-07-24 Qualcomm Incorporated GSM authentication in a CDMA network
EP1993611A4 (de) * 2006-03-16 2013-05-22 Alnylam Pharmaceuticals Inc Rnai-modulation von tgf-beta und ihre therapeutische verwendung
US8153604B2 (en) * 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
CN101489566B (zh) * 2006-05-19 2012-04-18 阿尔尼拉姆医药品有限公司 Aha基因的RNAi调控及其治疗性应用
US20140147441A1 (en) * 2006-09-12 2014-05-29 The General Hospital Corporation Compositions containing alpha-1-antitrypsin and methods for use
ATE544759T1 (de) 2007-07-21 2012-02-15 Albany Molecular Res Inc 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
WO2009023803A2 (en) * 2007-08-15 2009-02-19 Abbott Respiratory Llc Modulated release formulation for the delivery of one or more medicaments
CN102026970B (zh) 2007-11-21 2013-07-31 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4抑制剂
BRPI0907122B8 (pt) 2008-01-11 2021-05-25 Albany Molecular Res Inc compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos
JP2011511674A (ja) 2008-02-07 2011-04-14 ユニヴァーシティ オブ ワシントン 周方向エアロゾルデバイス
CA2720473A1 (en) 2008-04-04 2009-10-08 Calando Pharmaceuticals, Inc. Compositions and use of epas1 inhibitors
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
KR101675174B1 (ko) 2009-01-26 2016-11-10 이스라엘 인스티튜트 포 바이올로지컬 리서치 이환형 헤테로사이클릭 스피로 화합물
BR112012012945A2 (pt) 2009-11-25 2020-12-29 Arisgen Sa Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
EP2605816B1 (de) * 2010-08-20 2019-01-23 University Of Washington Umlaufende aerosolvorrichtung zur abgabe von arzneimitteln an die riechschleimhaut und das gehirn
CA2828884C (en) 2011-03-03 2021-04-27 Impel Neuropharma, Inc. Nasal drug delivery device
AU2012253569B2 (en) 2011-05-09 2018-02-15 Impel Pharmaceuticals Inc. Nozzles for nasal drug delivery
RU2657523C2 (ru) * 2011-11-03 2018-06-14 Олег Петрович Жирнов Фармацевтический аэрозольный состав ингибиторов протеаз с озон-сберегающим пропеллентом и его получение
HK1222358A1 (zh) 2013-04-28 2017-06-30 Impel Neuropharma Inc. 医用单位剂量容器
US10004764B2 (en) 2013-11-07 2018-06-26 University of Pittsburgh—of the Commonwealth System of Higher Education Red blood cell membrane-derived microparticles and their use for the treatment of lung disease
JP6753927B2 (ja) 2015-09-10 2020-09-09 インペル ニューロファーマ インコーポレイテッド 直列形経鼻送達デバイス
WO2019104192A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with inlet interface
JP7191099B2 (ja) 2017-11-21 2022-12-16 インペル ファーマシューティカルズ インコーポレイテッド 浸漬管を備えた鼻腔内装置
CN111936140A (zh) 2018-01-05 2020-11-13 英倍尔药业股份有限公司 通过精密鼻装置的双氢麦角胺的鼻内递送
WO2019136308A1 (en) 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
CN112135613A (zh) 2018-03-20 2020-12-25 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
US11517548B2 (en) 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease
CA3111275A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
CN113508111A (zh) 2018-12-31 2021-10-15 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
JP7213991B2 (ja) 2019-01-03 2023-01-27 インペル ファーマシューティカルズ インコーポレイテッド 経鼻薬送達器具
WO2020236658A1 (en) 2019-05-17 2020-11-26 Impel Neuropharma, Inc. Single-use nasal delivery device
CA3210753A1 (en) 2021-02-09 2022-08-18 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
WO2023198757A1 (en) 2022-04-14 2023-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582820A (en) 1982-12-23 1986-04-15 Research Corporation Orally administered biologically active peptides and proteins
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
EP0158441B2 (de) 1984-03-08 2001-04-04 Phares Pharmaceutical Research N.V. Liposombildende Zusammensetzung
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
DK179286D0 (da) 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
US4839111A (en) * 1987-02-02 1989-06-13 The University Of Tennessee Research Corporation Preparation of solid core liposomes
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5747445A (en) 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
DE69432224T2 (de) 1993-12-02 2003-12-04 Abbott Laboratories, Abbott Park Aerosole als darreichungsform mit cfc-freiem treibmittel
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
WO1996040057A2 (en) 1995-06-07 1996-12-19 Alliance Pharmaceutical Corp. Reverse fluorocarbon emulsion compositions for drug delivery
US5891465A (en) 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation

Also Published As

Publication number Publication date
AU1851900A (en) 2000-07-12
PT1143931E (pt) 2007-01-31
CA2353847A1 (en) 2000-06-29
NZ512272A (en) 2002-12-20
EP1143931B1 (de) 2006-10-04
DE69933472T2 (de) 2007-05-31
CA2353847C (en) 2007-03-06
ES2274651T3 (es) 2007-05-16
US6294153B1 (en) 2001-09-25
JP2002532537A (ja) 2002-10-02
JP3818852B2 (ja) 2006-09-06
AU759051B2 (en) 2003-04-03
MXPA01006377A (es) 2002-05-06
DE69933472D1 (de) 2006-11-16
WO2000037052A1 (en) 2000-06-29
EP1143931A1 (de) 2001-10-17
DK1143931T3 (da) 2007-02-12

Similar Documents

Publication Publication Date Title
ATE341309T1 (de) Pulmonale arzneistoffverabreichung
IT1317846B1 (it) Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
TR199701170T1 (xx) Beklometazon dipropionat i�in �l��lm�� doz inhaleri.
TR199701169T1 (xx) Salmeterol i�in �l��lm�� doz inhaleri.
TR199701168T1 (xx) Flutikazon Propionat i�in �l��lm�� doz inhaleri.
NZ509418A (en) Pharmaceutical formulations for aerosols with two or more active substances
HUP9801526A2 (hu) Inhaláló berendezés albuterol adagolására mért dózisban
UY24813A1 (es) Nuevas preparaciones medicamentosas acuosas para la produccion de aerosoles libres de gas propulsor
DE122011100049I1 (de) Stabile pharmazeutische Losungsformulierungen fur unter Druck stehende Inhaliergerate fur die Verabreichung abgemessener Dosen.
MY131733A (en) Aerosol drug formulations
ES2061591T3 (es) Administracion intranasal de polipeptidos en forma pulverizada.
BR9912170A (pt) Inaladores de dose medida pressurizados e formulações de aerossóis farmacêuticas
YU59092A (sh) Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja
MX9207205A (es) Formulacion farmaceutica en aerosol, bote para suministrarar dicha formulacion e inhalador de dosis dosificada que comprende dicho bote.
ATE234602T1 (de) Verabreichungsform zur abgabe von steigenden wirkstoffdosen
ATE388687T1 (de) Medikamentöse verabreichung von nikotin in form von kaugummi
GB2367005A (en) Pharmaceutical formulations and methods comprising intranasal morphine
ATE292453T1 (de) Antivirale arznei
TNSN01003A1 (fr) Appareil d'administration d'aerosols a comptage de dose dans des propulseurs hydrofluoroalcanes.
GB1114313A (en) Pharmaceutical compositions
ES2099649T3 (es) Nueva composicion farmaceutica destinada para la fabricacion de un polvo estable que contiene, a titulo de ingrediente activo, una asociacion de acido acetilsalicilico y de metoclopramida.
TNSN07289A1 (en) Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
US20100227008A1 (en) Salicylic acid acne spray formulations and methods for treating acne with same
AU2001258859A1 (en) Pralmorelin-containing nasal drop preparations
DE60318182D1 (de) Aerosol-formulierungen mit estern von 3,17-dihydroxyöstratrien-derivaten zur pulmonalen abgabe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties